The New York Times, July 11, 2022 (with Rebecca Robbins)
The Biden administration announced on Monday that it would buy 3.2 million doses of a Covid-19 vaccine from the Maryland pharmaceutical company Novavax that is expected to soon receive authorization in the United States.
If cleared by regulators, Novavax’s two-dose vaccine would become the fourth coronavirus vaccine available in the United States. It would be available at first as a primary immunization series for adults. After that initial authorization, the Food and Drug Administration could later authorize the vaccine as a booster shot.
The company hopes that its protein-based shot, a vaccine technology that has been widely used for decades, will appeal to Americans who declined to be vaccinated with shots using messenger RNA technology. About two-thirds of people in the United States are fully vaccinated. Continue reading “The U.S. government will buy 3.2 million doses of Novavax’s Covid vaccine.”